Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.

Saved in:
Bibliographic Details
Title: Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Authors: Turkova A; Medical Research Council Clinical Trials Unit, University College London, London, UK. Electronic address: a.turkova@ucl.ac.uk., Waalewijn H; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands., Chan MK; Medical Research Council Clinical Trials Unit, University College London, London, UK., Bollen PDJ; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands., Bwakura-Dangarembizi MF; University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe., Kekitiinwa AR; Baylor College of Medicine, Kampala, Uganda., Cotton MF; Children's Infectious Diseases Clinical Research Unit, Family Center for Research with Ubuntu, Department of Paediatrics and Child Health, University of Stellenbosch, Cape Town, South Africa., Lugemwa A; Joint Clinical Research Centre, Mbarara, Uganda., Variava E; Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Ahimbisibwe GM; Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda., Srirompotong U; Pediatric Department, Khon Kaen Hospital, Khon Kaen, Thailand., Mumbiro V; University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe., Amuge P; Baylor College of Medicine, Kampala, Uganda., Zuidewind P; Children's Infectious Diseases Clinical Research Unit, Family Center for Research with Ubuntu, Department of Paediatrics and Child Health, University of Stellenbosch, Cape Town, South Africa., Ali S; Medical Research Council Clinical Trials Unit, University College London, London, UK., Kityo CM; Joint Clinical Research Centre, Kampala, Uganda., Archary M; Department of Paediatrics and Child Health, King Edward VIII Hospital, Enhancing Care Foundation, University of KwaZulu-Natal, Durban, South Africa., Ferrand RA; London School of Hygiene & Tropical Medicine, London, UK., Violari A; Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Gibb DM; Medical Research Council Clinical Trials Unit, University College London, London, UK., Burger DM; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands., Ford D; Medical Research Council Clinical Trials Unit, University College London, London, UK., Colbers A; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, Netherlands.
Corporate Authors: ODYSSEY Trial Team
Source: The lancet. HIV [Lancet HIV] 2022 Sep; Vol. 9 (9), pp. e627-e637. Date of Electronic Publication: 2022 Jul 19.
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Equivalence Trial
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101645355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3018 (Electronic) Linking ISSN: 23523018 NLM ISO Abbreviation: Lancet HIV Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3018
DOI:10.1016/S2352-3018(22)00160-6